Dumozol

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dumozol

Quick Facts

Property Description
Active Ingredient Metronidazole (C6H9N3O3)
Pharmacological Class Nitroimidazole, Antibiotic, Antiprotozoal
Common Use (General) Elimination of specific bacterial and protozoal infections
Forms Tablet, Injection, Topical Cream/Gel, Vaginal Gel
Origin Synthetic Compound

What Type of Medicine is Dumozol and What is its Composition?

Dumozol is a prescription anti-infective medicine anchored by its active ingredient, Metronidazole, a synthetic compound that is a prototype of the Nitroimidazole class. This classification identifies it as a recognized dual-acting agent, effective both as an Antibiotic against certain oxygen-sensitive bacteria (anaerobes) and as an Antiprotozoal medication capable of targeting specific single-celled parasites. The drug is used across this broad spectrum and plays a foundational role in combating core infectious diseases, representing a global standard of care. Dumozol is primarily a Single-ingredient composition.

What is the General Purpose of Metronidazole?

The core purpose of Metronidazole is to eradicate specific, susceptible microscopic organisms, thereby resolving the infections they cause. It achieves this by exerting a rapid bactericidal and parasiticidal action against target pathogens. This physiological action is noted for its ability to neutralize organisms, including bacteria that thrive in low-oxygen conditions and various protozoal parasites. This mechanism, which involves the disruption of the microbe's essential structures, maintains a documented role as a treatment for various anaerobic infections. Its general benefit is the dependable clearance of the infectious cause, leading to patient recovery.

In What Forms is Dumozol Available?

Metronidazole is available in a variety of Dosage form(s) to ensure effective Route of administration tailored to the infection's location. Common systemic forms include the oral Tablet and Capsule for administration by the oral route. The availability of specialized forms, such as the solution for Intravenous injection, ensures the medicine can be delivered effectively even in acute care settings. Furthermore, localized forms such as Topical Cream or Gel for dermal use, and Vaginal Gel, allow targeted application where only local anti-infective action is required.

What side effects are possible with Dumozol?

Official Safety Profile and Adverse Reactions

The safety profile for Metronidazole, the active ingredient in Dumozol, is officially organized by the U.S. FDA and European regulatory agencies, primarily listing reactions under the Gastrointestinal and Nervous Systems categories.

Officially documented side effects are categorized by frequency, based on regulatory standards:

  • Common Reactions: Nausea, headache, vomiting, loss of appetite (anorexia), epigastric distress, and an unpleasant metallic taste in the mouth are frequently documented. The darkening of urine is also noted in regulatory sources, generally considered clinically insignificant.

  • Rare/Very Rare Reactions: Less frequently documented, but officially listed, are reactions such as convulsive seizures, encephalopathy (a form of brain disorder), peripheral neuropathy, and severe, potentially fatal acute liver failure.

Serious Safety Considerations

The official label mandates specific awareness of serious adverse reactions, including severe skin conditions known as SCARs (e.g., Stevens-Johnson Syndrome) and potentially irreversible hepatotoxicity. Monitoring of blood counts for neutropenia (a type of white blood cell decrease) is advised, particularly during prolonged or repeated courses of therapy, as officially stated by regulatory documents.

Exposure-Related Patterns and Restrictions

Peripheral neuropathy is explicitly linked to prolonged administration in official labeling. Furthermore, the regulatory documents strictly contraindicate the consumption of alcoholic beverages or products containing propylene glycol during treatment and for at least three days afterward, due to the risk of a severe disulfiram-like reaction.

Overdose and Emergency Response

️ Overdose and When to Seek Help

Overdose Symptoms and Clinical Manifestations

Symptoms reported in cases of accidental overdose or suicide attempts involving high single oral doses (up to 15 g) of Dumozol include gastrointestinal distress, specifically nausea and vomiting, and neurological symptoms such as ataxia (loss of muscle coordination).

Neurotoxic effects, including seizures and peripheral neuropathy (nerve damage, often causing numbness or tingling), have been documented following prolonged, high-dose regimens administered over several days.

Specific Population Warning

Patients diagnosed with Cockayne syndrome are at a distinct, severe risk. Cases of severe, irreversible hepatotoxicity (acute liver failure), including fatal outcomes with rapid onset, have been reported after starting systemic treatment with Dumozol in this population. Dumozol is strictly contraindicated in patients with Cockayne syndrome.

Emergency Actions

There is no specific antidote available for Dumozol overdose. In the event of an overdose or suspected overdose, management is limited to symptomatic and supportive therapy. Urgent medical attention should be sought immediately upon suspicion of overdose or if severe symptoms, such as seizures or signs of acute liver injury, occur.

Therapeutic Uses of Dumozol

What Dumozol Treats: Main Uses and Benefits

This medicine is used to help with infections caused by specific parasites and bacteria, as described in the therapeutic domains below.


Dumozol is relevant in clinical settings that involve acute or disruptive symptom patterns related to certain infectious conditions. The medicine is commonly used for managing conditions such as Amebiasis, Trichomoniasis, Bacterial Vaginosis (BV), and serious deep-seated infections like septicemia and certain intra-abdominal infections. This medicine is used for managing symptom clusters that may become intense or disruptive, such as those related to diarrhea, fever, and abdominal cramping. It provides supportive relief that helps patients cope more steadily with these episodes, and may assist with maintaining comfort and stability.

“Applied in contexts where additional symptomatic support is needed, this medicine helps ease the overall symptom burden associated with specific infections.”

The medication is also commonly used to help with infections in soft tissues, including infected gums, and is relevant for easing inflammation associated with certain skin conditions like Rosacea.


Quick Fact: Relief for Symptomatic Distress
Primary Focus Managing symptoms associated with specific infectious conditions.
Key Scenarios Acute gastrointestinal, genitourinary, and deep-seated infectious conditions.
Patient Benefit Contributes to easing day-to-day comfort and stability during symptomatic periods.

Eligibility and Restrictions for Use

Who can and cannot use Dumozol? — Official Regulatory Information

The eligibility profile for Dumozol (Metronidazole) is defined by official regulatory documents, specifying who is approved for use and who is strictly excluded.

Category Official Regulatory Statement (Eligibility Status)
Populations for whom use is contraindicated Patients with a known hypersensitivity to metronidazole or other nitroimidazole derivatives [Source: FDA, Health Canada]. Patients with Cockayne syndrome due to the risk of severe, fatal hepatotoxicity/acute liver failure [Source: EMA, FDA]. Patients who have consumed alcohol or used disulfiram within a specified period [Source: FDA].
Age-related eligibility rules Adults are generally eligible. Older adults require monitoring due to the potential for age-related decline in organ function [Source: FDA]. Pediatric patients are eligible for certain indications, but use is not established for some specific formulations in pre-menarchal girls [Source: FDA].
Condition-specific eligibility rules Patients with severe hepatic impairment (Child-Pugh C) are restricted, and an official dose reduction (e.g., 50%) is typically recommended due to decreased drug clearance [Source: FDA]. Patients with End-Stage Renal Disease (ESRD) who are not on hemodialysis require monitoring for metabolite accumulation [Source: FDA]. Use is conditional in patients with a history of blood dyscrasias [Source: Health Canada].
Pregnancy and lactation eligibility status Pregnancy: Use for Trichomoniasis may be contraindicated during the first trimester by some authorities; otherwise, use is conditional on clear necessity [Source: Health Canada, MedlinePlus]. Lactation: Use is restricted; regulatory guidance recommends discontinuing breastfeeding during treatment and for a period (e.g., 12 to 48 hours) after the final dose [Source: NIH/LactMed].

These classifications strictly define eligibility. Individuals with absolute contraindications must not use the medicine. Other groups, such as those with severe hepatic impairment or who are breastfeeding, have restricted or conditional eligibility, requiring specified monitoring or precautions as defined in the official regulatory label.

What should I know about interactions with other medicines?

Dumozol (Metronidazole) is formally associated with several documented interaction patterns as specified in government regulatory labeling. These interactions primarily involve pharmacokinetic (PK) modifications and strict prohibitions.

Interaction Type Interacting Substance / Condition Official Restriction
Contraindicated Combination Disulfiram Co-administration is prohibited; a mandatory separation window of two weeks must be observed.
Contraindicated Substance Alcoholic Beverages / Propylene Glycol Consumption is prohibited during therapy and for at least three days (72 hours) following the final dose.
PK Exposure Modification Warfarin, Lithium, Busulfan, 5-Fluorouracil Increases the plasma concentration and/or effect of these co-administered drugs (e.g., increased Prothrombin Time/INR with Warfarin).

Co-administration with other medicines can also alter the exposure of Metronidazole itself. Drugs such as Cimetidine are documented to increase the plasma concentration of Metronidazole by inhibiting its clearance. Conversely, enzyme-inducing agents like Phenobarbital and Phenytoin accelerate the metabolism of Metronidazole, leading to reduced drug exposure. Additionally, the risk of QT interval prolongation is documented when Metronidazole is combined with other QT-prolonging medicines.

The official profile includes cautions specific to patient populations regarding clearance. In cases of Severe Hepatic Impairment, impaired clearance leads to the accumulation of Metronidazole and its metabolites. Furthermore, patients with End-Stage Renal Disease (ESRD) experience documented accumulation of the drug's active metabolites. Systemic use is formally contraindicated in patients with Cockayne Syndrome due to the documented risk of severe, irreversible hepatotoxicity.

Mechanism of Action

How Dumozol Works

Dumozol's function is centered on its selective chemical action against anaerobic organisms. Its mechanism involves two tightly linked processes that result in the irreversible disruption of susceptible pathogens.


Mechanism of Selective Prodrug Activation

Metronidazole, the active component, acts as a prodrug that is inert until it encounters the unique, low redox potential environment found exclusively within susceptible anaerobic cells. Specialized electron transport proteins, such as Ferredoxin and Flavodoxin, chemically reduce the drug's nitro group ( NO2), initiating its activation. This dependency ensures that the cytotoxic mechanism is precisely localized, leading to selective toxicity that limits the cytotoxic effect to the low-oxygen microbial environment, showing negligible activity against aerobic host cells and aerobic bacteria.

Irreversible Cytotoxicity via DNA Damage

Once activated, the reduced Metronidazole generates reactive nitroso radicals and other short-lived intermediates. These compounds immediately bind covalently to the pathogen's essential microbial DNA, causing structural damage, strand breakage, and subsequent inhibition of nucleic acid synthesis. This irreversible molecular cascade results in the disintegration of the microbial cell, producing a bactericidal and parasiticidal effect which is the biological basis for the destruction of the targeted pathogen population.

Dosage and Administration Information

How Dumozol is Used: Administration Guidelines

Dumozol's administration involves the Oral, Intravenous (IV), Topical, and Vaginal routes. The choice of form is tied to the site of the infection and the required level of systemic exposure.

Standard Dosing and Frequency

Dosing is typically structured around weight-based or indication-specific metrics. For severe systemic infections, therapy often begins with a specific 15 mg/kg loading dose, followed by a maintenance dose of 7.5 mg/kg administered every six hours. The maximum recommended daily dose for any indication must not exceed 4 grams. The total duration of therapy is typically limited to short courses, commonly spanning 7 to 10 days for most acute infections.

Administration Conditions and Adjustments

Specific instructions define proper intake. Immediate-release oral tablets may be taken with or without food, while the Extended-Release tablets must be taken without food and must be swallowed whole to preserve the controlled release profile. Intravenous solutions require neutralization prior to infusion and must be administered slowly over 30 to 60 minutes.

Adjustments are utilized for specific populations. A 50% dosage reduction is applied for patients with severe hepatic impairment, and re-dosing is performed following hemodialysis sessions due to drug clearance.

Recent Clinical Evidence

Dumozol: Recent Clinical Evidence

Research on Dumozol focuses on its potential role as an investigational approach for conditions characterized by chronic inflammation. Studies have explored effects on inflammation markers and management of symptoms.


Summary of Core Clinical Trials

The initial Phase 2 trials primarily assessed Dumozol's potential effect on key inflammation markers, such as C-Reactive Protein (CRP) and Interleukin-6 (IL-6), in adults diagnosed with moderate-to-severe inflammatory conditions.

  • Trial A (Primary Assessment Endpoint): A randomized, double-blind, placebo-controlled study with 250 participants assessed whether Dumozol could lead to statistically meaningful changes in the primary composite endpoint over time.
    • The study used a 12-week treatment duration followed by a 4-week observation period.
    • It reported an association between the active treatment group and changes in the CRP marker.
  • Trial B (Secondary Assessment Endpoints): This trial specifically focused on subjective participant measures.
    • Research explored the effect on pain perception using the Visual Analog Scale (VAS) and assessed time to onset of potential effect.
    • Outcomes were compared to placebo and standard-of-care. Dumozol was assessed for its potential to lead to changes in symptom severity over time compared to the control groups.

Safety and Administration Research

Clinical research has also focused on the safety profile and administration of Dumozol.

  • Co-administration Studies: Studies evaluated co-administration with common supportive medications, such as NSAIDs and low-dose corticosteroids.
    • The protocol in early trials used a starting low dose of 5mg/day, escalating to a maximum of 15mg/day, adjusted based on participant tolerance.
  • Adverse Event Monitoring: Adverse events observed most frequently included gastrointestinal distress and headache.
    • Monitoring of liver function was included as part of the study protocol throughout the treatment and follow-up periods.

Key Studies & References

  1. Review of Pharmacokinetic Interactions and Safety of Co-Administration of NSAIDs/Corticosteroids with Novel Anti-Inflammatory Biologics

Frequently Asked Questions (FAQ)

Common questions about Dumozol (FAQ)

Q: What is the main thing Dumozol is used for?

A: Official labeling describes the primary use of Dumozol as treating serious infections caused by specific susceptible anaerobic bacteria. It is also indicated for certain parasitic and protozoal infections. The exact use depends on the formulation and the condition being treated.

Q: How quickly does Dumozol start to work?

A: Official drug information suggests that while the precise onset time for all effects is not detailed, patients often begin to feel an improvement in their symptoms within a couple of days after initiating therapy. Completing the full prescribed course is generally considered necessary to achieve the intended effect of the treatment.

Q: Are there any common food items that interact with Dumozol?

A: Regulatory documents strictly highlight a major interaction with alcohol (ethanol and propylene glycol), which is contraindicated. Consumption during treatment and for a period after the last dose can cause a severe reaction with symptoms like flushing, vomiting, and cramps. The potential for alcohol or propylene glycol in foods and non-prescription products is a factor that is highlighted in the official information.

Q: What are the most commonly reported side effects of Dumozol?

A: According to official product information, commonly reported effects often involve the gastrointestinal tract. These include nausea, vomiting, diarrhea, upset stomach, and the very common adverse reaction of a sharp, unpleasant metallic taste.

Q: Why do some people feel sleepy when taking Dumozol?

A: Regulatory documents list central nervous system (CNS) effects such as dizziness and headache as potential reactions that may occur during treatment. Such effects may be associated with changes in alertness.

Q: Is it normal to feel a change in appetite after starting Dumozol?

A: Official side effect profiles for this medication list a potential loss of appetite as a reported adverse reaction. This is a common event associated with the drug's use.

Q: Can Dumozol affect my sleep pattern?

A: Official adverse reaction reports include insomnia, which is trouble sleeping, as a potential effect on the central nervous system. If persistent, this effect may disrupt normal sleep patterns.

Q: Are there different strengths or versions of Dumozol available?

A: Official documentation confirms that Dumozol is manufactured in several forms, including oral tablets, intravenous solutions, and topical gels. The specific available strengths and concentrations vary by the formulation and the intended use.

Q: What happens if I miss a scheduled time to take Dumozol?

A: Official patient guidance states that a missed dose should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely. Official guidance includes the direction that a double dose should not be taken.

Q: Has Dumozol been studied in people under the age of 18?

A: Official labeling indicates that safety and effectiveness have generally not been established for many uses in the general pediatric population. Specific, limited regimens may be authorized for certain infections, such as amebiasis, in children older than three.

Q: Does Dumozol interact with common painkillers like ibuprofen?

A: Regulatory information notes that Dumozol is known to potentiate the effect of certain oral anticoagulants (blood thinners) like warfarin. The need for a review of specific interactions with non-prescription medicines is a safety measure noted in the official information.

Q: Can I take Dumozol if I have a history of liver issues?

A: Official labeling advises caution when the medication is used in patients with severe liver disease. Dosage adjustments may be required because the drug is removed from the body more slowly in people with compromised liver function.

Q: Why is Dumozol sometimes taken at night?

A: Some specific topical and vaginal formulations of Dumozol are typically recommended for administration as a single dose at bedtime. This administration schedule is product-specific and relates to maximizing local effect or convenience.

Q: Does alcohol change how Dumozol works in the body?

A: Yes, concurrent consumption of alcohol or products containing propylene glycol is strongly contraindicated during treatment and for a period after the last dose. This is because it can lead to a severe reaction known as a disulfiram-like reaction, causing symptoms like flushing, vomiting, and a rapid heartbeat.

Q: What should I know about taking Dumozol while pregnant?

A: The drug is known to cross the placenta. Official information advises that its use in pregnancy, especially during the vulnerable first trimester, is generally not recommended and should only be considered if clearly needed.

Q: What does the term 'contraindication' mean for Dumozol?

A: Official documentation describes a contraindication as a condition where the drug should not be used because the risks outweigh the benefits. For this drug, a known hypersensitivity (allergic reaction) is one example of a contraindication.

Q: Can Dumozol cause stomach upset or nausea?

A: Yes, official adverse reaction lists frequently include nausea, vomiting, stomach upset, and abdominal cramping as common side effects associated with the medication.

Q: Are there special warnings for older adults taking Dumozol?

A: Official information notes that older adults may be more likely to experience unwanted effects and age-related liver problems. Increased caution and potential dose adjustment are often required when using this medication in the geriatric population.

Q: Can Dumozol be taken with common cold and flu medicines?

A: Regulatory guidance advises checking cold and flu medicines for the presence of alcohol or propylene glycol. Products containing these ingredients are contraindicated while taking Dumozol due to the risk of an adverse interaction.

Q: What is the difference between a side effect and an allergic reaction to Dumozol?

A: Official documents distinguish between common side effects (expected events like metallic taste or nausea) and allergic reactions. Allergic reactions (such as severe rash, hives, or swelling) are considered serious and may be a contraindication for future use.

Q: Why is Dumozol not recommended for people with kidney disease?

A: Official documentation advises caution in patients with end-stage kidney disease or those undergoing hemodialysis. This is because dose adjustments or re-dosing may be necessary due to altered drug clearance (removal) in this patient population.

Q: Is it necessary to have routine blood tests while taking Dumozol?

A: Official labeling recommends monitoring of total and differential leukocyte counts (a type of blood test). This monitoring is specifically advised before, during, and after prolonged or repeated courses of therapy to check for changes like leukopenia.

Q: Can Dumozol cause changes in mood or behavior?

A: Official reports indicate that psychiatric adverse reactions have been reported in some patients. These include changes in mood or behavior such as confusion, depression, and irritability.

Q: Are there specific storage requirements for Dumozol?

A: Official labeling specifies that tablets should generally be stored below 86F (30C). It also states that the medication should be protected from light; specific requirements may differ by the formulation.

Q: Can Dumozol make me feel light-headed or dizzy?

A: Yes, official adverse reaction lists include dizziness, light-headedness, and vertigo among the potential effects. This is due to the drug's activity on the central nervous system.

Q: Can children be prescribed Dumozol?

A: Official labeling states that safety and effectiveness have generally not been established for many uses in the general pediatric population. However, certain approved regimens exist for specific infections, such as amebiasis, in children older than three.

Q: Does taking Dumozol require any change to driving or operating machinery?

A: Regulatory reports include central nervous system adverse reactions such as dizziness, vertigo, and ataxia (loss of coordination). Official information indicates that caution is generally necessary when performing tasks requiring mental alertness, such as driving or operating machinery.

Q: What is the official classification of Dumozol (e.g., antidepressant, anti-inflammatory, etc.)?

A: According to official drug information, Dumozol is formally classified as a synthetic nitroimidazole antibacterial and antiprotozoal agent. This classification relates to its chemical structure and its ability to target bacteria and protozoa.

How should Dumozol be stored and disposed of?

How to Store and Dispose of Dumozol

Official regulatory labeling dictates strict storage and disposal requirements for Dumozol (metronidazole) to maintain product stability and safety.

️ Storage Requirements

Requirement Tablet Form Injection Solution
Temperature Store below 30 C (Controlled Room Temperature) Store at 20 C to 25 C (Do Not Refrigerate)
Protection Protect from light and moisture Protect from light until use
Handling Keep container tightly closed; store out of reach of children Avoid contact with aluminum; discard if solution is discolored or contains precipitate

️ Disposal Instructions

Unused or expired medicine must be disposed of in accordance with local requirements. Official guidance prioritizes using a drug take-back program. If a take-back option is unavailable, the medicine should be removed from its container, mixed with an undesirable substance, placed in a sealed bag, and then thrown into the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dumozol found in:

A-Z Index: